Aktis Oncology is developing cancer radiation treatments intended to be more precise and potent compared to other radiotherapies. The startup is now out of stealth with $72 million in Series A financing.
Endocyte entered its targeted radioligand therapy, Lu-PSMA-617, into a Phase III study in June following Phase II data showing more than 60 percent response rate.
The progress in artificial intelligence (AI) is reshaping patient care, across various dimensions, from facilitating faster discharge to curating treatment plans and suggesting lifestyle changes.
The challenge with radiation and other cancer therapies is getting the right amount of treatment to the tumor and leaving healthy cells unscathed.